Comparing the current results to its competitors, Exagen Inc reported Revenue increase in the 2 quarter 2026 by 21.63 % year on year. The sales growth was above Exagen Inc 's competitors' average revenue growth of 8.57 %, achieved in the same quarter.
Exagen Inc 's Comment on Competition and Industry Peers
The company holds patent protection for its AVISE® technology used in diagnosing systemic lupus erythematosus (SLE), with patents valid through March 2034. In collaboration with Allegheny Health Network Research Institute, the company developed T-Cell Biomarkers, which were commercially launched in January 2025 as part of the AVISE® CTD test. Competitors include academic medical university-based clinics with in-house autoimmune testing, regional clinical laboratories such as Aqtual, Inc., and companies developing diagnostic, disease, or drug monitoring products, including AMPEL BioSolutions, LLC; DxTerity Diagnostics, Inc.; Genalyte Inc.; Immunovia AB; Oncimmune Holdings plc; and Progentec Diagnostics Inc. Key competitive factors in the market are the quality and strength of clinical and analytical validation data, confidence in diagnostic results, sales and marketing capabilities, reimbursement coverage, inclusion in clinical guidelines, cost-effectiveness, and ease of use. The company acknowledges that many competitors have greater brand recognition and more substantial financial, technical, research and development, and marketing resources. Additionally, competitors may offer lower-priced products or hold preferred network status, which could affect market acceptance and sales.
November 14, 2024
In a significant development in the field of autoimmune disease diagnostics, Exagen Inc. recently announced the successful validation and regulatory submission for new biomarkers related to lupus and rheumatoid arthritis. This breakthrough comes through their innovative AVISE CTD platform, designed to enhance diagnostic clarity for clinicians treating patients plagued by these complex conditions. The necessity for precise diagnostic tools in autoimmune diseases cannot be overstated, as these disorders are notoriously challenging to diagnose and treat effectively. With recent enhancements, Exagen aims to equip healthcare providers with improved insights, potentially leading to tailored treatment plans that ar...
Quest Diagnostics Inc operates as a leading provider of clinical laboratory and diagnostic information services, catering to patients, healthcare professionals, hospitals, and pharmaceutical companies. The company generates revenue through a comprehensive suite of diagnostic testing services, encompassing routine lab tests, advanced molecular diagnostics, and a variety of specialized tests tailored to support clinical decision-making and patient care.
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Labcorp Holdings Inc operates as a major healthcare diagnostics company, providing clinical laboratory tests and services to healthcare providers, pharmaceutical companies, and government agencies. Their business model emphasizes delivering accurate and timely test results to aid in patient diagnosis, treatment, and monitoring.
iSpecimen Inc's business model revolves around connecting researchers with the biospecimens they need for their scientific and medical studies. They serve as an intermediary platform that links healthcare organizations and biobanks to the research community, providing a streamlined process for sourcing human biosamples and associated data.
Sources:
Exagen Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Exagen Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
